Medtronic Announces First U.S. Clinical Trial Data On Transcatheter Valve For Congenital Heart Disease

Main Category: Heart Disease
Also Included In: Medical Devices / Diagnostics
Article Date: 11 Nov 2008 - 9:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Yesterday at the annual scientific sessions of the American Heart Association, the first U.S. clinical trial data on the Melody transcatheter pulmonary valve were presented. These findings also represent the first U.S. data on transcatheter valves in a population with congenital heart disease and the first reported U.S. data on the use of a transcatheter valve in the pulmonary position. The Melody valve is currently investigational in the U.S.

Data were presented on 66 patients enrolled at centers in Boston, Seattle, New York, Columbus, and Miami. Encouraging from a safety perspective was a high acute procedural success rate of 98 percent. At six-months follow up, maintenance of excellent valve competence was demonstrated as was a corresponding, clinically-significant, reduction of more than 18 percent in right ventricular volume. Valve competence was assessed by median pulmonary regurgitation fraction, which was down to 0 percent from a baseline of 30 percent.

Presenter of the data, Dr. Doff McElhinney, pediatric interventional cardiologist at Children's Hospital Boston, commented, "These data are very encouraging. Young patients with the types of congenital heart disease included in this study frequently require multiple open heart surgeries during the course of a lifetime. The Melody transcatheter valve is designed as a non-surgical alternative that will, at the very least, allow deferment of the next surgical intervention while protecting the heart from the strain of extra work. These multi-center data demonstrate that the Melody valve can be safely implanted with a high rate of procedural success. We have been encouraged by the excellent early function of the Melody valve and by the six-month clinical outcomes, which demonstrate clear improvements in heart size and valve function."

Of the U.S. congenital heart disease patients who require treatment each year for pulmonary valve dysfunction, approximately 1,500 are candidates for valve replacement with the Melody device. John Liddicoat M.D., general manager of the CardioVascular Structural Heart Disease business at Medtronic, commented, "The success of the Melody valve results directly from the collaborative approach Medtronic has taken with physicians and scientists to develop technology. This successful approach has also built the foundation for a much larger program to develop transcatheter valves for all valve positions." Dr. Liddicoat concluded, "Medtronic is well positioned to be the world leader in heart valve replacement and repair. The benefits for patients are immense as we continue to develop innovative technology that is safe, reliable and easy for doctors to deploy with repeatable and confident accuracy."

The Melody valve was designed for patients with congenital heart defects who have a surgically-placed conduit between the right ventricle and pulmonary artery. When the valves in these conduits fail, the Melody valve provides a non-surgical means to restore valve function and prolong the life of a conduit, reducing the number of open heart surgeries these patients require. Using the Ensemble® system, a physician navigates the Melody valve to the heart by threading it through the body's blood vessels, eliminating the need to open the chest, minimizing trauma and offering a quicker recovery than open heart surgery.

Melody, the world's first commercially available transcatheter valve, is available in 60 centers outside the United States following Canadian and European approval. Medtronic B.V., a wholly owned subsidiary of Medtronic, Inc., (NYSE: MDT) received CE Mark on the Melody Valve and Ensemble System in 2006.

About Medtronic

Medtronic, Inc., headquartered in Minneapolis, is the global leader in medical technology - alleviating pain, restoring health and extending life for millions of people around the world.

Medtronic, Inc.